Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...